<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133273</url>
  </required_header>
  <id_info>
    <org_study_id>I16014 (ONCOGRAM)</org_study_id>
    <nct_id>NCT03133273</nct_id>
  </id_info>
  <brief_title>Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)</brief_title>
  <acronym>ONCOGRAM</acronym>
  <official_title>Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncomédics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, chemotherapies are empirically administered to patients treated for colorectal
      cancer (CRC). Selection is based on the efficacy of a protocol previously determined on the
      largest number (consensus treatment), the decision-making process being weighted by patient's
      intrinsic criteria. However, each patient is unique, due to the inter- and intratumoral
      heterogeneity inherent in any cancer, partly explaining the unsatisfactory response rates
      observed for available chemotherapies. Functional sensitivity tests offer the possibility to
      adapt the treatment to each patient: they are based on an ex vivo study of the responses of
      the tumor cells (survival / death) to the different molecules / therapeutic combinations
      (chemotherapy or targeted therapy) likely to be administered to the patient. This response,
      translated into a tumor-specific sensitivity profile, can be used by the clinicians to
      determine the most appropriate therapeutic protocol. By increasing the therapeutic efficacy
      from the first line and reducing the deleterious side effects associated with multiple drug
      cycles, the sensitivity test transforms the consensus approach into personalized medicine,
      providing patients with improved progression free survival (PFS) associated with an
      improvement in the quality of life. Oncomedics has developed Oncogramme®, a CE-labeled in
      vitro diagnostic medical device that has already demonstrated the ability to predict
      chemosensitivity in a recent pilot study of metastatic CRC (prediction with 84% chance of
      success of tumor sensitivity to chemotherapy, vs. 50% maximum for chemotherapy administered
      according to the consensus method). The hypothesis that patients treated with a metastatic
      CRC for which systemic chemotherapy is adapted using Oncogramme® have better response rates,
      PFS and quality of life than patients treated according to usual practice, with optimization
      of the costs of care. To our knowledge, this is the only fully standardized test available,
      where each step and reagents of the procedure are mastered. The reliability of the procedure
      makes it possible to render a personalized result for each patient in 97% of the cases. In
      addition, the analysis is specifically centered on tumor cells using a method using fully
      defined, developed and validated media and reagents for each cancer, including CRC. The
      method of revealing the effect of the therapies identifies the proportion of dead cells in
      each condition, whatever their physiological state (proliferation / quiescence), by
      determining the percentage of living and killed cells, thus ensuring high sensitivity
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Anticipated">July 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients corresponding to the inclusion criteria and having a histologically proven metastatic CRC on biopsies or primary tumor excision and / or one or more metastatic sites will be recruited prospectively and randomized into two groups.
Usual care group: no Oncogramme will be made.
Oncogramme group: Taking of tumor fragments on the histological piece by an anatomopathological physician at the time of the histological examination and placing samples in the transport medium. The Oncogramme will be performed by Oncomedics on all specimens. Results will be returned to clinicians within 15 days.
For both groups, the adjuvant treatment will be decided in the multidisciplinary consultation meeting (MCM), according to the recommendations in force and adapted to the general medical condition of the patient. For patients in the Oncogramme group, chemotherapy will be adapted to Oncogramme.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The result of Oncogramme® will not give to the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of the progression or death of the patient.</measure>
    <time_frame>Year 1</time_frame>
    <description>The event studied is the occurrence of the progression or death of the patient during the year following the inclusion in the study. The progression of the patient is determined by the RECIST (Response Evaluation Criteria in Solid Tumors).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to first-line treatment administrated</measure>
    <time_frame>every month, up to 12 months</time_frame>
    <description>Percentage of patients in each response category to first-line treatment administered, evaluated by RECIST in each of the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Month 6 and Year 1</time_frame>
    <description>The event study is the death of the patient during the 6 months and the year following the inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific survival</measure>
    <time_frame>Month 6 and Year 1</time_frame>
    <description>The event considered is death due to illness during the 6 months and the year following the inclusion. The attribution of the death to the illness will be made by the adjudication committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost / Efficiency Ratio</measure>
    <time_frame>Year 1</time_frame>
    <description>Calculation of the Incremental Cost / Efficiency Ratio (ICER) expressed in euros per year of life gained without occurrence of death or progression to 1 year of the adapted chemotherapeutic treatment according to the results of Oncogramme® using EQ5D-5L s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost / Utility Ratio</measure>
    <time_frame>Year 1</time_frame>
    <description>Calculation of the Incremental Cost / Utility Ratio (ICUR) expressed in euros per QALY gained at 1 year of the adapted chemotherapeutic treatment according to the results of Oncogramme® using EQ5D-5L scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Month 3, Month 6, Month 9 and Year 1</time_frame>
    <description>Compare the quality of life of patients at 3 months, 6 months, 9 months and 1 year between the two groups using the EQ5D-5L questionary score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No adaptation of chemotherapy</measure>
    <time_frame>every month, up to 12 months</time_frame>
    <description>If there is no adaptation of the treatment to the results of Oncogramme®, describe the criteria that led to the failure to take into account the results of Oncogramme®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 and higher adverse events related to chemotherapy</measure>
    <time_frame>Year 1</time_frame>
    <description>Describe and compare in both groups the proportion of grade 3 and higher adverse events related to chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient is followed within the usual care for stage 4 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncogramme®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oncogramme®</intervention_name>
    <description>Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.</description>
    <arm_group_label>Oncogramme®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient with metastatic colon or rectal adenocarcinoma (Stage IV) who can benefit from
             standard systemic chemotherapy (monotherapy based on 5-FU, polychemotherapy type
             FOLFOX, FOLFIRI, FOLFIRINOX, associated or not with targeted therapies Adapted to the
             expression of BRAF and RAS, whatever the route of administration of the proposed, oral
             or intravenous therapies)

          -  Metastatic CRC diagnosed preoperatively on imaging or per-operative on macroscopic
             findings and proved by histological analysis (biopsy or surgical excision and if
             possible biopsies or excrescence on the metastatic sites)

          -  Measurable metastases according to RECIST

          -  Chemotherapy for curative or palliative purposes

          -  Patient with consent.

          -  Affiliate or beneficiary of a social security scheme.

        Exclusion Criteria:

          -  Formal contraindication to paraclinic exploration essential for patient follow-up

          -  Exclusive use of radiotherapy, targeted therapy, immunotherapy or hormone therapy,
             exclusive palliative support

          -  Patient with an absolute contraindication to the administration of chemotherapy

          -  Pregnant, lactating or non-contraceptive women for childbearing age women

          -  Patient with a difficulty of understanding the protocol

          -  Patient under protective measures (guardianship, curatorship, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muriel Mathonnet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel Mathonnet, MD</last_name>
    <phone>+33555056701</phone>
    <email>muriel.mathonnet@unilim.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Herafa</last_name>
    <phone>+33555058606</phone>
    <email>isabelle.herafa@chu-limoges.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean-Marc REGIMBEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>jean-Marc REGIMBEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bergonié Institut</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CH de BRIVE</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <zip>19100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinique des Cédres</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <zip>19100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS</name>
      <address>
        <city>Chambray-lès-Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medhi OUAISSI, MD</last_name>
      <phone>247478614</phone>
      <phone_ext>+33</phone_ext>
      <email>m.ouaissi@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Medhi OUAISSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Pezet, MD</last_name>
      <phone>+33473750494</phone>
      <email>dpezet@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Denis PEZET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne DUBOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline PEROTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier ANTOMARCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adnan ABOUKASSEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnes VIMAL-BAGUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Center</name>
      <address>
        <city>Guéret</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li CHEN, MD</last_name>
      <phone>555517041</phone>
      <phone_ext>+33</phone_ext>
      <email>l.chen@chgueret.fr</email>
    </contact>
    <investigator>
      <last_name>Li CHEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zekeriaou AMADOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos CHRISTOPOULOS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GHASSAN NAKHAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel MATHONNET, MD</last_name>
      <phone>+33555056701</phone>
      <email>muriel.mathonnet@unilim.fr</email>
    </contact>
    <contact_backup>
      <last_name>isabelle Herafa, MD</last_name>
      <phone>+33555058606</phone>
      <email>isabelle.herafa@chu-limoges.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Muriel MATHONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane BOUVIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niki CHRISTOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne FABRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdelkader TAIBI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis VALLEIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul CARRIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger DALOKO LONFO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne CHUFFART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylviane DURAND-FONTANIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophiane DERBAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric THUILLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault RIVAILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie LEBRUN-LY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAVAU-DENES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain LEGROS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHU de POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David TOUGERON, MD</last_name>
      <phone>549443751</phone>
      <phone_ext>+33</phone_ext>
      <email>david.tougeron@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>David TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint Junien</name>
      <address>
        <city>Saint-Junien</city>
        <zip>87200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric THUILLIER, MD</last_name>
      <email>frederic.thuillier@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric THUILLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibault RIVAILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophiane DERBAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médical MGEN Alfred Leune</name>
      <address>
        <city>Sainte-Feyre</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer Metastatic</keyword>
  <keyword>Chemosensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

